HC2 Announces Pansend Life Sciences Portfolio Company BeneVir Biopharm to be Acquired by Janssen Biotech, Inc. for up to $1.04 Billion

NYU Start up BeneVir, a company developing oncolytic immunotherapies based on research out of the laboratory of Dr. Ian Mohr is to be acquired by Janssen for $140 million with additional payments of $900 million based on meeting certain milestones. To read more

Thursday, May 10, 2018